Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
This website uses cookies to enhance your browsing experience. By using this site, you agree to our use of cookies. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. Please refer to the “External Data Transmission” section for further information.